Eli Lilly and Company

Lilly Icos LLC

Kerry John Hartauer

Wayne Douglas Luke

Gordon Nelson Arbuthnot

Brian Weston Dalder

Robert Eugene Stratford, Jr

Arvind L Thakkar

Stephanie Ann Sweetana

Lowell L Gibson

Julian L Stowers

Gregory Alan Stephenson

Neil R Anderson

Martha A Kral

Fadia Najjar Bashore

Michael Dean Minnett

Eugene Clark Rickard

Cheryl Ann Tingle

Robert E Stratford

This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.

Benzothiophenes, formulations containing same, and methods

The present invention is directed to pharmaceutical formulations containing 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxypheny)benzo[b]thiophene or a salt thereof; stabilized to oxidation or other forms of decomposition by incorporation of a stabilizing agent selected from methionine, acetylcysteine, cysteine or salts thereof.

Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof

This invention provides compounds of formula Iand pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.

A compound of structural formula (I), and pharmaceutically acceptable salts and solvates thereof, wherein the compound is in free drug particulate form, is disclosed.

Beta-carboline drug products

Benzothiophenes formulations containing same and methods

This invention provides orally administerable pharmaceutical formulations comprising raloxifene, its ethers or esters, or a pharmaceutically-acceptable salt thereof, in combination with a hydrophilic carrier composition.

Solid orally administerable raloxifene hydrochloride pharmaceutical

This invention provides solid orally administerable pharmaceutical formulations comprising raloxifene hydrochloride, a surfactant being sorbitan fatty acid ester or a polyoxyethylene sorbitan fatty acid ester, polyvinylpyrrolidone, and a water soluble diluent which is polyol or sugar.

Growing community of inventors

Carmel, IN, United States of America

Kerry John Hartauer